SI1646656T1 - Äśloveĺ ke protitelesne molekule za il-13 - Google Patents

Äśloveĺ ke protitelesne molekule za il-13

Info

Publication number
SI1646656T1
SI1646656T1 SI200431681T SI200431681T SI1646656T1 SI 1646656 T1 SI1646656 T1 SI 1646656T1 SI 200431681 T SI200431681 T SI 200431681T SI 200431681 T SI200431681 T SI 200431681T SI 1646656 T1 SI1646656 T1 SI 1646656T1
Authority
SI
Slovenia
Prior art keywords
antibodies
domains
antibody molecules
human
molecules
Prior art date
Application number
SI200431681T
Other languages
English (en)
Inventor
Phillip David Monk
Lutz Jermutus
Ralph Raymond Minter
Celia Patricia Shorrock
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SI1646656T1 publication Critical patent/SI1646656T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200431681T 2003-07-15 2004-07-15 Äśloveĺ ke protitelesne molekule za il-13 SI1646656T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24
PCT/GB2004/003059 WO2005007699A2 (en) 2003-07-15 2004-07-15 Human antibody molecules for il-13
EP04743400A EP1646656B1 (en) 2003-07-15 2004-07-15 Human antibody molecules for il-13

Publications (1)

Publication Number Publication Date
SI1646656T1 true SI1646656T1 (sl) 2011-07-29

Family

ID=32298405

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431681T SI1646656T1 (sl) 2003-07-15 2004-07-15 Äśloveĺ ke protitelesne molekule za il-13

Country Status (21)

Country Link
US (6) US7829090B2 (sl)
EP (4) EP2292660B1 (sl)
JP (1) JP4891074B2 (sl)
KR (1) KR101168815B1 (sl)
CN (2) CN1852923B (sl)
AT (1) ATE500274T1 (sl)
AU (1) AU2004256976B2 (sl)
BR (1) BRPI0412651B8 (sl)
CA (3) CA2805464A1 (sl)
DE (1) DE602004031622D1 (sl)
DK (1) DK1646656T3 (sl)
ES (1) ES2361079T3 (sl)
GB (2) GB0407315D0 (sl)
IL (1) IL172869A (sl)
NZ (1) NZ544662A (sl)
PL (1) PL1646656T3 (sl)
PT (1) PT1646656E (sl)
RU (1) RU2387667C2 (sl)
SI (1) SI1646656T1 (sl)
WO (1) WO2005007699A2 (sl)
ZA (1) ZA200601340B (sl)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
MXPA06000258A (es) * 2003-07-15 2006-07-03 Cambridge Antibody Tech Moleculas de anticuerpo humano para interleucina-13.
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AU2004274909B8 (en) * 2003-09-15 2010-06-10 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
DK1711528T3 (da) 2003-12-23 2012-08-20 Genentech Inc Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
WO2006113614A2 (en) * 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Service National Institutes Of Health Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells
GB2430883B (en) * 2005-09-30 2008-03-19 Cambridge Antibody Tech Interleukin-13 antibody composition
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
CN101578298A (zh) * 2006-01-24 2009-11-11 杜门蒂斯有限公司 结合il-4和/或il-13的配体
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP3339445B1 (en) * 2006-09-08 2020-07-15 AbbVie Bahamas Ltd. Interleukin -13 binding proteins
WO2008048871A2 (en) * 2006-10-18 2008-04-24 Centocor, Inc. Cynomolgus il-13 mutein proteins, antibodies, compositions, methods and uses
JP2010527916A (ja) * 2007-04-23 2010-08-19 ワイス・エルエルシー Ｉｌ−１３関連障害を治療する方法および組成物ならびにその治療をモニターする方法
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
BRPI0906261A2 (pt) * 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
BRPI0915825A2 (pt) 2008-07-08 2015-11-03 Abbott Lab proteínas de ligação à prostaglandina e2 usos das mesmas
US8399630B2 (en) 2008-08-20 2013-03-19 Centocor Ortho Biotech Inc. Engineered anti-IL-13 antibodies, compositions, methods and uses
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
MX2013004212A (es) * 2010-10-15 2013-09-02 Medimmune Ltd Terapias para mejorar la funcion pulmonar.
AR084342A1 (es) 2010-12-16 2013-05-08 Genentech Inc Diagnostico y tratamientos relacionados con la inhibicion de th2
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
EP2734236A4 (en) 2011-07-13 2015-04-15 Abbvie Inc METHOD AND COMPOSITIONS FOR TREATING ASTHMA WITH ANTI-IL-13 ANTIBODIES
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
WO2013098420A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of isolating human antibodies
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
BR112016008694A2 (pt) 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
ES2754271T3 (es) * 2013-12-17 2020-04-16 Novo Nordisk As Polipéptidos escindibles por enteroquinasa
BR112016013347B1 (pt) 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
CN105934254A (zh) * 2014-01-27 2016-09-07 免疫医疗有限责任公司 作为哮喘肺中il-13活化的外周生物标志的二肽基肽酶-4（dpp4/cd26）
CN106170497A (zh) 2014-02-07 2016-11-30 免疫医疗有限责任公司 检测人类骨膜蛋白的新型测定
CA2937556A1 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
US10066267B2 (en) 2014-04-11 2018-09-04 Novartis Ag Methods of selectively treating asthma using IL-13 antagonists
ES2755395T3 (es) 2014-06-06 2020-04-22 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
KR20220119179A (ko) 2014-06-18 2022-08-26 메디뮨 엘엘씨 N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지
CN107206079A (zh) 2015-01-09 2017-09-26 免疫医疗有限责任公司 检测人dpp‑4的测定法
WO2016113217A1 (en) * 2015-01-12 2016-07-21 Medimmune Limited Il-13 binding proteins and uses thereof
CN107430117A (zh) 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
SI3303395T1 (sl) 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
CA2988115A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
SG11201803817PA (en) 2015-11-19 2018-06-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017139290A1 (en) * 2016-02-10 2017-08-17 Medimmune, Llc Tralokinumab delivery device
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
WO2017198148A1 (zh) * 2016-05-18 2017-11-23 上海开拓者生物医药有限公司 一种il-13抗体及其制备方法和应用
JP7274417B2 (ja) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
TWI825025B (zh) 2017-08-31 2023-12-11 日商田邊三菱製藥股份有限公司 包含il-33拮抗劑的子宮內膜異位症治療劑
CN109810192A (zh) * 2017-11-21 2019-05-28 深圳福沃药业有限公司 抗-il-13抗体
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
GB201802487D0 (en) * 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
SG11202109003QA (en) 2019-03-06 2021-09-29 Regeneron Pharma Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2020261281A1 (en) 2019-06-27 2020-12-30 Ramot At Tel-Aviv University Ltd. Semaphorin 3a antibodies and uses thereof
TW202136302A (zh) * 2019-12-09 2021-10-01 比利時商艾伯霖克斯公司 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US20230287099A1 (en) 2020-03-23 2023-09-14 Medimmune Limited Methods for treating atopic dermatitis and related disorders
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
WO2022197782A1 (en) 2021-03-17 2022-09-22 Receptos Llc Methods of treating atopic dermatitis with anti il-13 antibodies
GB202108379D0 (en) 2021-06-11 2021-07-28 Medlmmune Ltd Methods for treating a topic dermatitis and related disorders
TW202325731A (zh) 2021-08-16 2023-07-01 美商麥迪紐有限責任公司 抗ｉｌ—１３抗體調配物
CN118076636A (zh) 2021-09-15 2024-05-24 德米拉公司 Il-13抑制剂用于治疗结节性痒疹
WO2023052408A1 (en) 2021-09-28 2023-04-06 Medimmune Limited Methods for treating atopic dermatitis and related disorders
CA3235096A1 (en) 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
AU5010793A (en) 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
CN1085953A (zh) * 1992-08-21 1994-04-27 先灵公司 人白细胞介素13
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO2000034784A1 (en) 1998-12-10 2000-06-15 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
AU778392B2 (en) 2000-03-03 2004-12-02 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US20040234499A1 (en) * 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
CA2464695A1 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
SI1461428T1 (sl) * 2001-12-03 2012-07-31 Alexion Pharma Inc Postopek za proizvodnjo hibridnih protiteles
WO2003086451A1 (en) * 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
AU2003243189B2 (en) * 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
DK1711528T3 (da) 2003-12-23 2012-08-20 Genentech Inc Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
AU2004256976B2 (en) 2010-12-23
CA2532799A1 (en) 2005-01-27
PT1646656E (pt) 2011-06-07
CN1852923A (zh) 2006-10-25
US7947273B2 (en) 2011-05-24
EP2292660A2 (en) 2011-03-09
US7935343B2 (en) 2011-05-03
ATE500274T1 (de) 2011-03-15
US20090123478A1 (en) 2009-05-14
ES2361079T3 (es) 2011-06-13
CA2804901C (en) 2018-04-24
GB2403952B (en) 2005-09-21
US20050065327A1 (en) 2005-03-24
DE602004031622D1 (de) 2011-04-14
RU2006104618A (ru) 2007-08-27
EP2314624A2 (en) 2011-04-27
GB2403952C (en) 2006-06-16
GB2403952A (en) 2005-01-19
US20120052060A1 (en) 2012-03-01
CA2804901A1 (en) 2005-01-27
WO2005007699A2 (en) 2005-01-27
WO2005007699A8 (en) 2005-10-27
EP2292660A3 (en) 2011-10-12
GB2403952C2 (en) 2013-02-13
EP2314624B1 (en) 2016-05-04
GB0415857D0 (en) 2004-08-18
KR20110023914A (ko) 2011-03-08
BRPI0412651A (pt) 2006-09-26
US9315575B2 (en) 2016-04-19
CA2805464A1 (en) 2005-01-27
EP3064510A1 (en) 2016-09-07
ZA200601340B (en) 2008-12-31
PL1646656T3 (pl) 2011-08-31
US20180230209A1 (en) 2018-08-16
EP2292660B1 (en) 2016-07-06
US9856317B2 (en) 2018-01-02
US20160280779A1 (en) 2016-09-29
EP1646656A2 (en) 2006-04-19
DK1646656T3 (da) 2011-05-30
US20070128192A1 (en) 2007-06-07
IL172869A0 (en) 2006-06-11
EP2314624A3 (en) 2011-06-29
JP2007537702A (ja) 2007-12-27
EP1646656B1 (en) 2011-03-02
CN104987419A (zh) 2015-10-21
RU2387667C2 (ru) 2010-04-27
NZ544662A (en) 2009-09-25
BRPI0412651B8 (pt) 2021-05-25
KR101168815B1 (ko) 2012-07-27
BRPI0412651B1 (pt) 2020-04-22
US7829090B2 (en) 2010-11-09
IL172869A (en) 2013-10-31
GB0407315D0 (en) 2004-05-05
JP4891074B2 (ja) 2012-03-07
AU2004256976A1 (en) 2005-01-27
CA2532799C (en) 2013-04-02
WO2005007699A3 (en) 2005-05-12
CN1852923B (zh) 2015-05-27

Similar Documents

Publication Publication Date Title
GB2403952C (en) Human antibody molecules for IL-13
GEP20115226B (en) P-cadherin antibodies
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
EP1978032A3 (en) Binding molecules
WO2002002640A3 (en) Antibodies to human mcp-1
AU2002326531A1 (en) Monoclonal antibodies to activated erbb family members and methods of use thereof
WO2003085089A3 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
RS50858B (sr) Anti-tnf antitela, kompozicije, metode i njihove upotrebe
TW200801037A (en) Organic molecules
EP1538207A4 (en) ANTI-HUMAN MCP-1 ANTIBODY OF HUMAN ORIGIN AND CORRESPONDING ANTIBODY FRAGMENT
JP2011527902A5 (sl)
RS52332B (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
EP2371862A3 (en) Compositions monovalent for CD40L binding and methods of use
PE20020319A1 (es) ANTICUERPOS PARA IL-1ß HUMANA
WO2003093320A3 (en) Antibodies specific for human cd22 and their therapeuatic and digagnostic uses
GB0130543D0 (en) Human antibodies and their use
EP1492870A4 (en) ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
WO2005060457A3 (en) Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2005000896A3 (en) Polypeptides that bind an anti-tissue factor antibody and uses thereof
WO2023039611A3 (en) Tfr antigen binding proteins and uses thereof
TH64455A (th) สารภูมิต้านทาน mcp-1 ในมนุษย์
TH53886A (th) แอนติบอดี้ต่อ il-1b ในมนุษย์